Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Sales (2020 - 2025)

Barinthus Biotherapeutics' Return on Sales history spans 6 years, with the latest figure at 209.65% for Q4 2025.

  • For Q4 2025, Return on Sales fell 20556.0% year-over-year to 209.65%; the TTM value through Dec 2025 reached 209.65%, down 20556.0%, while the annual FY2024 figure was 4.09%, 8749.0% up from the prior year.
  • Return on Sales reached 209.65% in Q4 2025 per BRNS's latest filing, up from 239.58% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 16718.0% in Q4 2021 to a low of 21126.0% in Q2 2025.
  • Average Return on Sales over 5 years is 324.35%, with a median of 40.72% recorded in 2021.
  • Peak YoY movement for Return on Sales: soared 1675264bps in 2021, then plummeted -1672128bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 16718.0% in 2021, then plummeted by -100bps to 3.28% in 2022, then plummeted by -2694bps to 91.58% in 2023, then soared by 96bps to 4.09% in 2024, then crashed by -5029bps to 209.65% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Return on Sales are 209.65% (Q4 2025), 239.58% (Q3 2025), and 21126.0% (Q2 2025).